Title of article
Regional citrate anticoagulation for hemodialysis: A safe and efficient method
Author/Authors
Jarraya, Faical Sfax University Hospital - Department of Nephrology, Tunisia , Mkawar, Khaled Sfax University Hospital - Department of Nephrology, Tunisia , Kammoun, Khawla Sfax University Hospital - Department of Nephrology, Tunisia , Hdiji, Abdelhamid Sfax University Hospital - Department of Nephrology, Tunisia , Yaich, Somaya Sfax University Hospital - Department of Nephrology, Tunisia , Kharrat, Mahmoud Sfax University Hospital - Department of Nephrology, Tunisia , Charfeddine, Khaled Sfax University Hospital - Department of Nephrology, Tunisia , Hmida, Mohamed Ben Sfax University Hospital - Department of Nephrology, Tunisia , Mahfoudh, Hichem Sfax University Hospital - Department of Nephrology, Tunisia , Ayedi, Fatma Sfax University Hospital - Department of Biochemistry, Tunisia , Hachicha, Jamil Sfax University Hospital - Department of Nephrology, Tunisia
From page
533
To page
534
Abstract
Regional citrate anticoagulation (RCA) was proposed by Pinnik et al as an alternative to heparin for intermittent hemodialysis (HD), [1] was first used by Morita et al. in 1961. [2] More recently, it is used for continuous hemodialysis [3] in high risk bleeding patients. Citrate achieves anticoagulation by forming complexes with ionized calcium. During HD, the citrate effect is most likely confined to the extra corporeal system because about 60% of the formed citrate complexes are removed from the blood by the dialyzer.
Journal title
Saudi Journal of Kidney Diseases and Transplantation
Journal title
Saudi Journal of Kidney Diseases and Transplantation
Record number
2675125
Link To Document